Lilly(US:LLY) Xin Lang Cai Jing·2025-12-10 00:00Core Viewpoint - Eli Lilly, a major American pharmaceutical company, announced an investment of over $6 billion to build an active pharmaceutical ingredient manufacturing facility in Huntsville, Alabama, aimed at expanding domestic production and strengthening the drug supply chain [1][2]. Group 1: Investment and Production Plans - The new facility will be the third plant that Eli Lilly plans to invest in within the United States [1][2]. - The plant will produce small molecule synthesis and peptide drugs, including the company's first oral GLP-1 weight loss drug, orforglipron, which is expected to receive U.S. approval in early 2024 [1][2]. Group 2: Construction Timeline and Job Creation - Construction of the Alabama facility is expected to begin in 2026 and be completed by 2032 [3]. - The facility is projected to create 450 jobs in the region, including positions for engineers, scientists, operators, and laboratory technicians, as well as 3,000 construction jobs [3].